QIAGEN NV to acquire Cellesis Limited
QIAGEN NV has reached an agreement to acquire Cellestis Limited for approximately AU$341 million in cash, providing QIAGEN with access to a novel ‘pre-molecular’ technology that offers a new dimension in disease detection not currently possible with other diagnostic methods.
The acquisition of Cellestis will provide QIAGEN with exclusive rights to QuantiFERON technology, a proprietary approach for disease detection and monitoring.
QuantiFERON is complementary to QIAGEN’s portfolio of molecular diagnostics. Its high sensitivity and ability to provide clinically relevant information means that this technology can be used ahead of DNA- or RNA-based molecular testing. Greater use of QuantiFERON technology can help guide and drive the use of traditional DNA- and RNA-based molecular diagnostics.
L'Oréal-UNESCO For Women In Science Fellows announced for ANZ
This year's program honours four women who are reshaping what leadership in research looks...
Peter Beattie appointed Chair of Brandon BioCatalyst
Brandon BioCatalyst has announced new board appointments to continue the scaling of Australian...
Virologist receives GSK Award for AI-based disease detection
Professor Edward Holmes has received the 2025 GSK Award for Research Excellence for his use of...
